The 53rd Annual Meeting of the American Society of Hematology December 10, 2011

The 53rd Annual Meeting of the American Society of Hematology aims to provide information on nearly 30 important areas of clinical progress, including groundbreaking advances in genomic studies of hematologic malignancies, new management strategies for bone failure syndromes, and innovative hematopoietic stem cell transplantation methodologies for benign disorders. The event also includes two education program sessions held jointly with the American Association of Blood Banks that will focus on transfusion medicine.

•Ronald Herbst will present “Live Cell Imaging Captures Immune Cell-mediated Killing of Precursor-B Acute Lymphoblastic Leukemia Cells Targeted with Anti-CD19 (MEDI-551) Antibodies: Support for Macrophage and NK Cell in Vivo Activity.”
•Robert Kreitman will present “Moxetumomab pasodotox, an anti-CD22 recombinant immunotoxin, in relapsed/refractory hairy cell leukemia (HCL): updated results from a phase 1 study.”
•Alan Wayne will present "An anti-CD22 immunotoxin, moxetumomab pasudotox Phase 1 study in patients with pediatric acute lymphoblastic leukemia (ALL): updated results."